The estimated Net Worth of Dorothy E Puhy is at least $13.3 million dollars as of 1 February 2021. Ms. Puhy owns over 5,000 units of Abiomed stock worth over $1,093,146 and over the last 21 years she sold ABMD stock worth over $11,912,394. In addition, she makes $294,996 as Lead Independent Director at Abiomed.
Sign up
Ms. Puhy ABMD stock SEC Form 4 insiders trading
Dorothy has made over 44 trades of the Abiomed stock since 2007, according to the Form 4 filled with the SEC. Most recently she sold 5,000 units of ABMD stock worth $1,747,350 on 1 February 2021.
The largest trade she's ever made was exercising 15,822 units of Abiomed stock on 16 January 2018 worth over $579,718. On average, Dorothy trades about 1,908 units every 37 days since 2003. As of 1 February 2021 she still owns at least 2,869 units of Abiomed stock.
You can see the complete history of Ms. Puhy stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dorothy Puhy biography
Dorothy E. Puhy serves as Lead Independent Director of the Company. Ms. Puhy served as Executive Vice President and Chief Operating Officer for the Dana-Farber Cancer Institute from 2012 until her retirement in March 2019. Ms. Puhy previously served as the Chief Financial Officer of the Dana-Farber Cancer Institute from 1994 to 2012 and as its Assistant Treasurer from 1995 to 2012. From 1985 to 1994, Ms. Puhy held various financial positions at the New England Medical Center Hospitals, Inc., including Chief Financial Officer from 1989 to 1994. Ms. Puhy received her Bachelor of Arts from the University of Pennsylvania and her Master of Business Administration from the Wharton School of Business at the University of Pennsylvania.
What is the salary of Dorothy Puhy?
As the Lead Independent Director of Abiomed, the total compensation of Dorothy Puhy at Abiomed is $294,996. There are 10 executives at Abiomed getting paid more, with Michael Minogue having the highest compensation of $16,612,800.
How old is Dorothy Puhy?
Dorothy Puhy is 68, she's been the Lead Independent Director of Abiomed since 2005. There are 2 older and 15 younger executives at Abiomed. The oldest executive at Abiomed Inc. is Jeannine Rivet, 72, who is the Independent Director.
What's Dorothy Puhy's mailing address?
Dorothy's mailing address filed with the SEC is 1775 WEST OAK COMMONS CT NE, , MARIETTA, GA, 30062.
Insiders trading at Abiomed
Over the last 21 years, insiders at Abiomed have traded over $148,507,587 worth of Abiomed stock and bought 232,354 units worth $4,276,073 . The most active insiders traders include Michael R Minogue, Eric A Md Rose et David M Weber. On average, Abiomed executives and independent directors trade stock every 16 days with the average trade being worth of $5,341,900. The most recent stock trade was executed by Martin P Sutter on 17 February 2022, trading 4,000 units of ABMD stock currently worth $1,258,840.
What does Abiomed do?
Abiomed Europe GmbH, Aachen / Germany, as affiliate of Abiomed Inc. headquartered in Danvers, Massachusetts, USA, is a leading medical technology company in the field of circulatory support. Its products aim to enable heart recovery by improving blood circulation and/or heart pump function.
What does Abiomed's logo look like?
Complete history of Ms. Puhy stock trades at Abiomed, MiMedx Inc et NEOS ETF Trust
Abiomed executives and stock owners
Abiomed executives and other stock owners filed with the SEC include:
-
Michael Minogue,
Chairman of the Board, President, Chief Executive Officer -
Todd Trapp,
Chief Financial Officer, Vice President -
Andrew Greenfield,
Vice President, Chief Commercial Officer -
David Weber,
Chief Operating Officer, Senior Vice President -
Michael R. Minogue,
Chairman, CEO & Pres -
Michael Howley,
Vice President and General Manager, Global Sales -
Todd A. Trapp,
CFO & VP -
Dr. David M. Weber,
Sr. VP & COO -
Marc A. Began,
VP, Gen. Counsel & Sec. -
Andrew J. Greenfield,
VP & Chief Commercial Officer -
Dorothy Puhy,
Lead Independent Director -
Paul Thomas,
Independent Director -
Martin Sutter,
Independent Director -
Jeannine Rivet,
Independent Director -
Christopher Van Gorder,
Independent Director -
Eric Rose,
Independent Director -
Marc Began,
Vice President, General Counsel, Secretary -
Karen Mahoney,
Head of Global HR -
Michael G. Howley,
VP & GM of Global Sales -
Sarah Karr,
Communications Mang. -
Ingrid Goldberg Ward,
Director of Investor Relations -
Dr. Thorsten Siess Ph.D.,
VP & CTO -
Henri A Termeer,
Director -
Gorder Chris Van,
Director -
William J Bolt,
SVP, DA and QA -
Michael John Tomsicek,
Vice President, CFO -
W Gerald Austen,
Director -
Myron L Rolle,
Director -
Louis E Lataif,
Director -
Robert Bowen,
Chief Financial Officer -
Ronald W Dollens,
Director -
Daniel J Sutherby,
CFO -
Inc Abiomed,
Director -
Connell Desmond Jr O,
Director -
Paul Fireman,
Director -
Javier Jimenez,
VP Operations -
Anthony W Bailey,
VP, Business Development -
David M Lederman,
Chairman, CEO & President -
Charles B Haaser,
Principal Financial Officer -
Eugene D Rabe,
SVP, Global Sales & Services -
Christopher D Macdonald,
SVP Global Sales -
Sheila Marie Flaherty,
VP, General Counsel -
Robert T V Kung,
SVP, Chief Scientific Officer -
Edward E Berger,
VP, Strat. Plan & Ext. Comm. -
Patricia A. Fitch,
Vice President of Sales -
Raymond J Kelley,
VP Marketing -
David Gottlieb,
Director -
John F Obrien,
Director -
Gary Stickel,
VP of HR -
Karim Benali,
VP Product Development -
Robert Farra,
VP Engineering & Manufacturing -
Stephen C Mc Evoy,
VP and General Counsel -
Paula A Johnson,
Director